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OBJECTIVE—We evaluated predictors of progression to diabetes in children with high-risk
HLA genotypes and persistent islet autoantibodies.
RESEARCHDESIGNANDMETHODS—TheDiabetesAutoimmunityStudyintheYoung
(DAISY) followed 2,542 children with autoantibodies measured to GAD, IA-2, and insulin.
RESULTS—Persistent islet autoantibodies developed in 169 subjects, and 55 of those pro-
gressed to diabetes. Children expressing three autoantibodies showed a linear progression to
diabetes with 74% cumulative incidence by the 10-year follow-up compared with 70% with two
antibodies and 15% with one antibody (P , 0.0001). Both age of appearance of ﬁrst autoanti-
body and insulin autoantibody (IAA) levels, but not GAD or IA-2 autoantibodies, were major
determinants of the age of diabetes diagnosis (r =0 . 7 9 ,P , 0.0001).
CONCLUSIONS—In the DAISY cohort, 89% of children who progressed to diabetes
expressed two or more autoantibodies. Age of diagnosis of diabetes is strongly correlated with
age of appearance of ﬁrst autoantibody and IAA levels.
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M
ost of the trials to prevent type 1A
diabetes target individuals in the
preclinical phase of the disease,
marked by the presence of persistent islet
autoantibodies (1). Screening for auto-
antibodies to insulin (IAA) (2), GAD (3),
and protein tyrosine IA-2 (ICA512) (4) is
the mainstay of risk prediction (5). Fac-
tors correlating and potentially predictive
of age of diagnosis of children followed
from birth are less well characterized.
RESEARCH DESIGN AND
METHODS
Study population
The Diabetes Autoimmunity Study in the
Young (DAISY) has followed two cohorts
of young children at increased risk of
diabetes (n = 2,542), including relatives
and general population children screened
forsusceptibilityHLA-DR/DQgenotypes.
The details of screening and follow-up
were previously published (6). Autoanti-
bodies to GAD, IA-2, and insulin (IAA)
were measured in all samples at 9, 15,
and24monthsofage,andannuallythere-
after; if positive, antibodies were mea-
sured every 3–6m o n t h s .I n f o r m e d
consent was obtained, and the Colorado
Multiple Institutional Review Board ap-
proved all study protocols.
Islet autoantibodies
Measurement of islet autoantibodies was
performedinthelaboratoryofDr.George
Eisenbarth at the Barbara Davis Center
using radioimmunoassays, as described
previously (7).
Statistical analysis
Statistical analyses were performed using
PRISM(GraphPadSoftware,Inc.,LaJolla,
CA) and SAS software (SAS, Inc., Cary,
NC). The IAA, GAD, and IA-2 levels were
log-transformed for analyses. Survival
analysis was performed for progression
to diabetes using the log-rank test. Follow-
up time was deﬁned as the time from
initial positive autoantibody test for each
subject.Multiplelinearregressionwasused
to evaluate potential predictors of age of
diabetes diagnosis in subjects who had
their ﬁrst autoantibody measurement be-
fore 1.5 years (n =3 8 ) .
RESULTS—Duringamedian follow-up
of 7.0 years, 169 children developed
persistent islet autoantibodies (one or
more autoantibody on at least two con-
secutive visits), and 55 of those pro-
gressed to diabetes. A total of 89% of
children who progressed to diabetes, so
far, expressed two or more autoanti-
bodies.
In a life-table analysis (Fig. 1A),
children expressing two or more auto-
antibodies showed a nearly linear progres-
sion to diabetes. The cumulative incidence
of diabetes by 10 years of follow-up dif-
feredsigniﬁcantlybythenumberofauto-
antibodies: 74, 70, and 15% in patients
with three, two, and one autoantibodies,
respectively (P , 0.0001). There was no
signiﬁcant difference in the progression
to diabetes between relatives and general
population subjects. The high-risk DR3/
4-DQB1*0302 genotype was an addi-
tional predictor of a 10-year progression
to diabetes in children expressing one
autoantibody (30 vs. 13%; P = 0.035) or
two autoantibodies (100 vs. 54%; P =
0.029), but not among patients express-
ingthreeautoantibodies(73.6vs.75.1%;
P =0.91).Childrenwithpersistentlypos-
itive IAA levels had a higher progression
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BRIEF REPORTrate to diabetes (100% by 5.6 years) than
childrenwithﬂuctuatingIAAlevels(63%
by the 10-year follow-up) (P , 0.0001)
(Fig. 1B).
The age of appearance of autoanti-
body was a major determinant of the age
at diabetes diagnosis, accounting for 47%
ofthevariance(r=0.69,P,0.0001).The
mean age of appearance of ﬁrst autoanti-
body varied by group: 6.1, 5.5, and 3.8
years for one, two, or three antibodies,
respectively (P = 0.0007).
We performed multiple regression
analyses,includingageattheﬁrstpositive
antibody, initial number of positive anti-
bodies, family history, high-risk HLA-
DR3/4, ethnicity, and IAA, GAD, and
IA-2 levels (both initial and mean levels).
In multiple regression analyses,including
initial IAA, GAD, and IA-2 levels, the age
at diabetes diagnosis was best predicted
by initial IAA level, initial number of
positive antibodies, and age at the ﬁrst
positive antibody (r =0 . 8 3a n dP ,
0.0001) (Fig. 1C). When analyzing
mean IAA, GAD, and IA-2 levels, only
mean IAA levels and age of the ﬁrst pos-
itive antibody were signiﬁcant predictors
of age of diabetes diagnosis (r = 0.79, P ,
0.0001) (Fig. 1D).
CONCLUSIONS—In DAISY, 89% of
children who progressed to diabetes ex-
pressed two or more autoantibodies with
cumulative incidence of 74% by age 10
years for individuals expressing three
autoantibodies. Risk of progression to
diabetes in siblings has been shown to
be inﬂuenced by age of diagnosis of pro-
band, autoantibody number and levels,
and genetic susceptibility markers (8–
11). These results are consistent with
studies from Finland (12,13) regarding
high risk, and the most signiﬁcant risk
factors were young age at seroconversion,
positivity for multiple autoantibodies,
high autoantibody levels, and persistent
positivity for IAA (11,14). In a Finnish
study of siblings of diabetic children re-
cruited at a mean age of 9.9 years, 76% of
the variance in the age at diagnosis was
explained by age at ﬁrst sampling, initial
IA-2 level, and initial number of detect-
able autoantibodies (11).
In this prospective study, major de-
terminants of the age of diagnosis of
diabetes were age at ﬁrst positive auto-
antibody and IAA levels, but not GAD or
IA-2 levels. It is likely that with time,
additional children will progress to di-
abetes. However, initial IAA levels alone
have limitedpredictedvalue (r=0.36,P=
0.029), whereas mean levels over time
strongly correlate with time to diabetes.
The predictive value of mean levels of
insulin autoantibodies, but not GAD or
IA-2 levels, may relate to hypothesized
unique biologic importance of insulin
autoimmunity b-cell destruction (15).
Figure 1—A: Progression to diabetes in children positive for anti-islet autoantibodies (n = 169). There was no signiﬁcant difference in the pro-
gression rate between subjects with two or three positive antibodies. B: Progression to diabetes in children with persistently positive IAA levels and
ﬂuctuating IAA levels (n = 88). IAA Pers Pos, persistently positive IAA levels; Fluctuat IAA, ﬂuctuating IAA levels. C: Predicted age of diagnosis of
diabetes (initial IAA, GAD, and IA-2 levels) (n = 38). Analysis done in all subjects who had their ﬁrst antibody measurement before 1.5 years and
progressed to diabetes. D: Predicted age of diagnosis of diabetes (mean IAA, GAD, and IA-2 levels) (n = 38). Analysis was done in all subjects who
had their ﬁrst antibody measurement before 1.5 years and progressed to diabetes.
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Predicting age of diabetes diagnosisThebestpredictivemodelstoidentify
children at highest risk for diabetes de-
pendonthegeneticmarkersavailable,the
age at which the screening commences,
and our ability to repeat autoantibody
testing over time. Potential public health
applications will need to optimize com-
bination of these factors and cost of
screening.
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